原发性肝癌血管性血友病因子裂解酶的表达水平及意义
被引量:3
Clinical significance of the dysregulated expression of von Willebrand factor-cleaving protease in patients with primary hepatocarcinoma
摘要
血管性血友病因子(von Willebrand factor, vWF)是介导癌细胞与血小板结合以及癌血栓与内皮下组织粘附的重要"桥梁"[1].
出处
《中华肝脏病杂志》
CAS
CSCD
北大核心
2005年第10期795-796,800,共3页
Chinese Journal of Hepatology
参考文献5
-
1Oleksowicz L, Mrowiec Z, Schwartz E, et al. Characterization of tumor-induced platelet aggregation: the role of immunorelated GP Ⅰb and GPⅡb/Ⅲa expression by MCF-7 breast cancer cells. Thromb Res, 1995, 79: 261-274.
-
2Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem, 1998, 67: 395-424.
-
3Oleksowicz L, Bhagwati N, DeLeon-Fernandez M. Dificient activity of von Willebrand's factor-cleaving protease in patients with disseminated malignancies. Cancer Res, 1999, 59: 2244-2250.
-
4Lee TE Bouhassira EE, Lyubsky S, et al. ADAMTS13, the von Willebrand factor cleaving metalloprotease, is expressed in the perisinusoidal cells of the liver. Blood, 2002, 100(Suppl.1): 497a.
-
5Mannucci PM, Canciani MT, Forza I, et al. Changes in health and disease of the metalloprotease that cleaves von Willebrand factor. Blood,2001, 98: 2730-2735.
同被引文献9
-
1Fukikawa K, Suzuki H, McMullen B, et al. Purification of human yon Willebrand factor-cleaving protease and its identification as a new member of the metalloproteinase family[J]. Blood, 2001,98(6) :1662-1666.
-
2Yoo G, Blomback M, Gustafsson S, et al. Decreased levels of yon willebrand factor-cleaning protease in coronary heart disease and thrombotic thrombocytopenic purpure: study of a simplified method for assaying the enzyme activity based on ristocetin-induced platelet aggregation[J]. Brit J Haematol, 2003,121(1) :123-129.
-
3Rieger M, Marmucci PM, Kremer Hovinga JA, et al. ADAMTS13 autoantibodies in patients with thrombotic mieroangiopathies and other immunomediated diseases [J].Blood, 2005,106(4) : 1262-1267.
-
4Mannucci PM, Vanoli M, Forza I, et al. Von Willebrand factor-cleaving protease (ADAMTS13) in 123 patients with connective tissue disease(systemic lupus erythematosus and systemic sclerosis) [J]. Thrombosis, 2003,188(8) :914-917.
-
5Weening J J, D'Agati VD, Schwartz MM, et al. The classification of glomerulone-phritis in systemic lupus erythematosus revisited[J]. Kidney Int, 2004,15 (2) : 241-250.
-
6Rick ME, Molls S, Taylor MA. Clinical use of rapid collagen binding assay for yon Willebrand factor cleaving protease in patients with thrombotic thrombo-cytopenic purpura[J].Thromb Haemost, 2002,88 (4) .. 598-604.
-
7Gerritsen HE,Robles R, Lammle B, et al. Partial amino acid sequence of purfied von willebrand factor-cleaving protease [J].Blood,2001,98(6) : 1654-1661.
-
8Levy GG, Nichols WC, Lian EC, et al. Mutation in a member of the ADAMTS13 gene family cause thrombotic thromobeytopenic purpura[J]. Nature,2001,413 (6855) : 488-494.
-
9Mannucci PM, Canciani MT, Forza I, et al. Changes in health and disease of the metalloprotease that cleaves von willebrand factor[J]. Blood,2001,98(9):2730-2735.
引证文献3
-
1韦忠恒,浦涧,汪建初,马燕飞,韦邦宁,陆涛.中晚期肝癌凝血及纤溶功能变化及其临床意义[J].中国现代医学杂志,2009,19(3):430-432. 被引量:3
-
2胡坤,刘金霞,卢国元,王兆钺,苏健,阮长耿.慢性肾病患者血浆vWF与vWF裂解酶的检测及临床意义[J].江苏医药,2010,36(4):373-376. 被引量:2
-
3刘沨,王荣珍,杨爱军,王晨昱,李敏.vWF和vWF-CP在紫癜性肾炎患者中的表达及意义[J].基因组学与应用生物学,2019,38(9):4335-4342. 被引量:3
二级引证文献8
-
1钟腾猛,肖进,黄俊玲.急性等容血液稀释对老年肝癌病人围手术期凝血功能的影响[J].血栓与止血学,2013,19(4):161-163. 被引量:4
-
2覃慧敏,周晓琳.回生口服液辅助治疗肝癌对凝血及纤溶功能影响的分析[J].现代预防医学,2014,41(22):4200-4202. 被引量:3
-
3王亿平,王东,徐文静,吕勇,魏玲,茅燕萍,胡顺金,刘家生,章雪莲.参地颗粒对慢性肾炎脾肾亏虚证患者肾小球内皮细胞的干预作用[J].中国中西医结合急救杂志,2016,23(4):360-363. 被引量:12
-
4蒋强,张燕军,张倩,王海亭,蒋忠仆.凝血及纤溶功能变化在原发性肝癌介入治疗中的临床意义[J].临床放射学杂志,2016,35(10):1590-1592. 被引量:9
-
5王亿平,徐文静,王东,金华,章雪莲,茅燕萍.参地颗粒对系膜增生性肾小球肾炎大鼠内皮细胞的干预作用[J].中成药,2017,39(11):2369-2372. 被引量:5
-
6周威,陈贡斌,刘海燕,郭银谋,林全德.血浆指标与骨肉瘤术后深静脉血栓的相关分析[J].中国矫形外科杂志,2020,28(21):1963-1967. 被引量:4
-
7代彦林,张霞,高敏,韩姗姗,丁樱.紫癜性肾炎患儿血清sFlt-1、vWF水平变化及其意义[J].山东医药,2021,61(12):51-53. 被引量:3
-
8司雨,李乐,陈小玲,司函瑞,史大臻,刘金平,李平亚,焦玉凤.西洋参总皂苷对急性血瘀模型大鼠的作用研究[J].中南药学,2021,19(5):851-856. 被引量:1
-
1曹文静,ZHENG X Long.血管性血友病因子裂解酶的研究进展[J].中华检验医学杂志,2008,31(6):704-707. 被引量:1
-
2郭小芳,成兴波,卢国元.2型糖尿病患者血管并发症与血浆血管性血友病因子裂解酶的关系[J].苏州大学学报(医学版),2006,26(3):438-440. 被引量:1
-
3杨军,王苏燕,张勇,王光辉,邝孛,江振涛,文格波.冠心病患者血浆血管性血友病因子裂解酶、生长分化因子15水平变化及相关性分析[J].山东医药,2013,53(43):21-23. 被引量:5
-
4董宁征,刘芳,季顺东,阮长耿.急性心肌梗死和脑梗死患者血浆中ADAMTS13的测定及意义[J].中华血液学杂志,2008,29(3):161-163. 被引量:6
-
5陈劲松,匡希斌.急性冠脉综合征与血管性血友病因子裂解酶的关系[J].中国心血管病研究,2007,5(9):662-664. 被引量:3
-
6胡上高,周建耀.过敏性紫癜患者血浆血管性假血友病因子的变化及临床意义[J].临床荟萃,2009,24(2):147-147.
-
7陈劲松,匡希斌,陈海燕,陈琳.急性冠状动脉综合征血浆血管性血友病因子及其裂解酶[J].岭南心血管病杂志,2007,13(2):118-121.
-
8沈蕾(综述),董宁征(审校),阮长耿(审校).ADAMTS13与炎症反应[J].国际输血及血液学杂志,2010(1):45-48.
-
9孟新.vWF-CP水平及GRACE评分评估冠心病患者危险分层的价值[J].中国老年学杂志,2015,35(22):6430-6431. 被引量:1
-
10毛建平,姜振宇,李薇,吴天姊,夏珊珊,吴婕.血栓性血小板减少性紫癜的发病机制及治疗进展[J].深圳中西医结合杂志,2006,16(6):390-394. 被引量:2